ISIS 2922 antisense compound: Began a Phase I trial

Isis Pharmaceuticals Inc. (ISIP) Eisai Co. Ltd. Product: ISIS 2922 antisense compound Indication: Treat cytomegalovirus in AIDS patients who have failed current therapies and whose disease is progre...